0.11
+2.24%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TME Pharma
Its shares trade on Euronext Paris under the ticker ALTME.PA. It has been listed since 10 September 2018. In the fiscal year to 31 December 2024, it reported revenue of €19,000 and a net loss of €5.7m. At that date it held total assets of €3.4m and shareholders' equity of €1.6m.
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Sept 2018
- Employees
- 13
- Website
- tmepharma.com ↗
Leadership
Pay as last reported
- Dr. Maurizio PetitbonIndependent Chairman of the Supervisory Board, since 2016€4,100
- Mr. Diede Van Den OudenChief Executive Officer, Director, since 2025
- Ms. Susan ColesIndependent Deputy Chairperson of the Supervisory Board, since 2021€53,105
- Dr. Jarl JungneliusChief Medical Officer
- Dr. Cornelis IzeboudIndependent Member of the Supervisory Board€44,050
- Dr. Lee SchalopIndependent Member of the Supervisory Board€26,187
- Dr. Alexandra GlucksmannMember of the Supervisory Board€10,508
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company focuses on therapeutics targeting the tumor microenvironment (TME) in clinical stage.
- Specializes in technology that breaks tumor protection barriers against the immune system.
- Has clinical programs in glioblastoma and pancreatic cancer with reported results.
Weaknesses
- Operates with only 13 full-time employees.
- IPO occurred in 2018, indicating limited recent capital market activity.
- Headquartered in Berlin, Germany, which may limit access to certain markets.
Opportunities
- Further development of clinical programs in glioblastoma and pancreatic cancer is planned.
- Potential for combination therapies with other treatments to enhance therapeutic impact.
- Technology neutralizes chemokines in the TME, offering a unique approach in biotechnology.
Threats
- Clinical-stage company faces high risks associated with drug development.
- Limited employee count may hinder scalability and operational capacity.
- Dependence on successful clinical outcomes for future growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.